Donald L. Siegel

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Dept. Pathology & Lab Med, Penn-Presbyterian Medical Center
Director, ACGME-accredited Fellowship Program in Blood Banking/Transfusion Medicine, Hospital of the University of PA
Medical Director, AABB-accredited Blood Bank and Apheresis Unit, Hospital of the University of Pennsylvania
Member for Oversight of Blood Usage, Clinical Effectiveness and Quality Improvement Committee, Hospital of the University of PA
Medical Director, FACT-accredited cell collection and processing facilities for Hematopoietic Stem Cell Transplant Program, Hospital of the University of Pennsylvania
Member, Executive Committee, Dept of Pathology & Lab Med, University of Pennsylvania School of Medicine
Attending Physician, Division of Transfusion Med, Dept. Pathology & Lab Med, Hospital of the University of PA
Founding Director, Division of Transfusion Medicine & Therapeutic Pathology, Hospital of the University of PA
Member, Cell & Vaccine Production Facility Advisory Committee, University of Pennsylvania School of Medicine
Medical Director, FACT-accredited Clinical Cell Vaccine and Production Facility, University of Pennsylvania
Medical Director, Penn Medicine Blood Donation Center, Hospital of the University of PA
Department: Pathology and Laboratory Medicine

Contact information
510 Stellar-Chance Laboratories
422 Curie Blvd.
Philadelphia, PA 19104
Office: (215) 898-9655
Education:
Sc.B. (Biophysics)
Brown University, 1977.
Ph.D. (Biophysics)
Harvard University, 1983.
M.D.
University of Pennsylvania, 1987.
Permanent link
 

Description of Research Expertise

Research Interests

Production and characterization of pathogenic human monoclonal auto- and alloantibodies

Research Summary

My laboratory is interested in characterizing the human immune response to auto- and alloantigens on a molecular level in order to understand more about human immune repertoire development. Our goal is to use this information to develop specific therapeutic agents that down-regulate immune responses in the settings of autoimmune disease such as immune hemolytic anemias and thrombocytopenias, transfusion reactions, hemolytic disease of the newborn, and acute rejection of solid organ allografts.
To approach these problems experimentally, we have combined Fab/phage-display technology with a novel cell-surface panning method to isolate large arrays of clinically significant human monoclonal antibodies from individual patients. This approach has enabled us to study the genetic and immunological properties of pathogenic auto- and alloantibodies.

Description of Itmat Expertise

Dr. Siegel's research focuses on the study of the molecular genetics of human auto- and alloantibodies responsible for blood cell-related disorders such as immune cytopenias (ITP, AIHA, TTP), hemolytic transfusion reactions, and hemolytic disease of the newborn. The Siegel laboratory has developed several phage display-related technologies for the cloning of human immune repertoires and the production of human monoclonal antibodies. These studies have led to the development of novel diagnostic reagents and antibodies with therapeutic potential.

Selected Publications

Gao, C., Liu, Y., Zhang, H., Zhang, Y., Fukuda, M.N., Palma, A.S., Kozak, R.P., Childs, R.A., Nonaka, M., Li, Z., Siegel, D.L., Hanfland, P., Peehl, D.M., Chai, W., Greene, M.I., Feizi, T.: Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array. J. Biol. Chem. in press, 2014.

O'Doherty, U., Siegel, D.L.: Transfusion Reactions. The Intensive Care Manual, 2nd edition. Lanken, P.N., Manaker S., Kohl B.A., Hanson C.W. (eds.). Elsevier Saunders, Philadelphia, Page: 450-456, 2014.

Garfall A.L., Dougherty A.L., Vogl D.T., Weiss B.W., Cohen A.D., Mangan P.A., O’Doherty U., Siegel D.L., Porter D.L., Stadtmauer E.A.: Stem cell mobilization with Plerixafor + G-CSF in comparison to cyclophosphamide + G-CSF is associated with inferior time-to-progression after autologous stem cell transplantation for multiple myeloma. Blood 2013.

Azzato E., Carpenter H., Miszczanczuk M., Dinh L-H., DeMuth F., Magee D., Aqui N., Kambayashi T., Siegel D.L., Sachais B.S.: Prospective monitoring of cryoprecipitate resulting in decreased product waste. Transfusion 2013.

Mangalmurti N.S., Friedman J.L., Wang L.C., Stolz D.B., Muthukumaran G., Siegel D.L., Schmidt A.M., Lee J.S., Albelda S.M.: The receptor for advanced glycation end products mediates lung endothelial activation by RBCs. Am J Physiol - Lung Cell Mol Physiol 304: L250-263, 2013.

Garfall A.L., Dougherty A.L., Vogl D.T., Weiss B.W., Cohen A.D., Mangan P.A., O’Doherty U., Siegel D.L., Porter D.L., Stadtmauer E.A.: Stem cell mobilization with Plerixafor + G-CSF in comparison to cyclophosphamide + G-CSF is associated with inferior time-to-progression after autologous stem cell transplantation for multiple myeloma. Blood 2013.

Kouno M., Lin C., Schechter N., Siegel D.L., Stanley J.R: Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus monoclonal antibody. J Invest Dermatol 133: 2212-2220, 2013.

Casina V., Wenbing H., Hanby H., Siegel D.L., Mayne L., Englander S.W., Zheng X.L.: Hydrogen-deuterium exchange coupled with mass spectrometry identifies a novel autoantibody binding epitope and substrate recognition site in ADAMTS13 protease. Blood 2013.

Siegel, D.L.: “The Expanding Role of Transfusion Medicine in Personalized Medicine and Therapeutics” Ortho On-Demand Webinar series: "Transfusion Medicine -- What’s New and What’s Next" October 2012.

Mangalmurti N.S., Friedman J.L., Siegel D.L., Lee J.S., Albelda S.M.: Banked red cells induce Receptor for Advanced Glycation End products (RAGE) expression on lung endothelium and mediate vascular activation through RAGE. Blood 120: SCI-47, 2012.

back to top
Last updated: 05/12/2014
The Trustees of the University of Pennsylvania